Squarepoint’s BridgeBio Pharma BBIO Stock Holding History

Squarepoint’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,600	Closed	-$352K	–	4273
2025 Q4	$352K	Sell	4,600 -18,900	-80%	-$1.24M	﹤0.01%	3479
2025 Q3	$1.22M	Buy	23,500 +1,600	+7%	+$78K	﹤0.01%	2511
2025 Q2	$946K	Sell	21,900 -1,000	-4%	-$36.4K	﹤0.01%	2712
2025 Q1	$792K	Buy	+22,900	New	+$772K	﹤0.01%	2866

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Squarepoint's BBIO Position: Q2 2026 in Review

Squarepoint increased its BridgeBio Pharma (BBIO) stake by 114% in Q2 2026, buying an estimated $44.5M and bringing the position to 1,191,732 shares worth $88.8M. The position accounts for 0.1% of the portfolio, ranked #193.

Squarepoint first reported a position in BBIO in Q2 2020 and has held it in 19 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Squarepoint held 1,191,732 shares of BridgeBio Pharma worth $88.8M as of Q2 2026.
Squarepoint bought 635,408 BridgeBio Pharma shares in Q2 2026, an estimated $44.5M.
BridgeBio Pharma made up 0.1% of Squarepoint's portfolio in Q2 2026, its #193 holding.
Squarepoint first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 19 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.